Barclays on Universal Health Services (UHS) After Investor Meetings; Business Improvement Should Materially Benefit
Get Alerts UHS Hot Sheet
Price: $170.53 --0%
Rating Summary:
11 Buy, 19 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 10 | New: 22
Rating Summary:
11 Buy, 19 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 10 | New: 22
Join SI Premium – FREE
Barclays maintains an 'Overweight' on Universal Health Services (NYSE: UHS) price target of $71.00.
Analyst, Joshua R. Raskin, said, "We were recently able to host UnitedHealth for a series of investor meetings including a group meeting, with the main takeaway being the clear differentiation that UnitedHealth brings relative to the traditional managed care sector...Looking at the company today, we believe that UnitedHealth is particularly well positioned relative to its peer group. Our conclusion is that UnitedHealth Group is quietly operating at an accelerated pace, while external market forces pressure the stock's valuation."
For an analyst ratings summary and ratings history on Universal Health Services click here. For more ratings news on Universal Health Services click here.
Shares of Universal Health Services closed at $38.15 yesterday.
Analyst, Joshua R. Raskin, said, "We were recently able to host UnitedHealth for a series of investor meetings including a group meeting, with the main takeaway being the clear differentiation that UnitedHealth brings relative to the traditional managed care sector...Looking at the company today, we believe that UnitedHealth is particularly well positioned relative to its peer group. Our conclusion is that UnitedHealth Group is quietly operating at an accelerated pace, while external market forces pressure the stock's valuation."
For an analyst ratings summary and ratings history on Universal Health Services click here. For more ratings news on Universal Health Services click here.
Shares of Universal Health Services closed at $38.15 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Barclays Starts Centrus Energy Corp. (LEU) at Equalweight
- BNP Paribas Exane Downgrades Lanxess AG (LXS:GR) (LNXSF) to Underperform
- Wolfe Research Starts First Tracks Biotherapeutics (TRAX) at Outperform
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
BarclaysSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share